Studies have shown that Elesclomol–Cu in prostate cancer can enhance cellular response to docetaxel by activating copper accumulation dependent on the DLAT/mTOR pathway (which occurs both in vitro and in vivo) [18]. Here, DLAT is linked to prostate carcinoma.